Ferrocenes in medicinal chemistry; a personal perspective by Sansook, Supojjanee et al.
Ferrocenes in medicinal chemistry; a personal perspective
Article  (Accepted Version)
http://sro.sussex.ac.uk
Sansook, Supojjanee, Hassell-Hart, Storm, Ocasio, Cory and Spencer, John (2019) Ferrocenes 
in medicinal chemistry; a personal perspective. Journal of Organometallic Chemistry, 905. pp. 1-
17. ISSN 0022-328X 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/87944/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
1 
 
Ferrocenes in medicinal chemistry; a personal perspective 
Supojjanee Sansook, a,b Storm Hassell-Hart b, Cory Ocasiob,c,  John Spencer b,* 
a Faculty of Science and Technology, Princess of Naradhiwas University, Narathiwat, 
Thailand, 96000. 
b Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, 
Brighton, East Sussex, BN1 9QJ, UK. 
c The Francis Crick Institute, London, NW1 1AT (UK). 
 
ABSTRACT 
We present a short review of some of our recent work mainly targeting cancer-related 
oncoproteins through the development of primarily novel air- and water- stable iron-
based organometallic agents. This work was presented at the recent ISBOMC19 
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The chemistry and history of ferrocene is well understood, spanning about 70 years 
and, recently, medicinal applications have come to the fore[1],[2]. The aim of this mini-
review is to highlight our work on the development of mostly ferrocene-based agents 
based on work covered over a period of approximately 10 years. 
Air- and water-stable, metal-based complexes allow us to probe biological targets in 
ways we cannot achieve with carbon-based molecules. Metal incorporation can also 
alter the pharmacokinetics of a drug, benefiting from ligand-metal exchange reactions 
and enable unique modes of action, such as reactive oxygen species generation or 
photorelease, which can add to further DNA damage for example[3,4][5]. Much of this 
is covered in many excellent treatises[6–9][10]. Pioneering work by the Meggers group 
described the generation of highly selective kinase inhibitors with  sub-nanomolar 
potency[11] by making use of the “hypervalent carbon” effect. In these examples, 
improved selectivity and potency were achieved by taking advantage of metal-based 
octahedral complexes, whereas similar carbon-based compounds, constrained by sp3 
tetrahedral geometry, gave inferior biological activities. The literature abounds with 
examples of ferrocene-based bioactive molecules, including the following 
representative examples: Taxol analogue 1[12], a redox-active ferrocifen 2[13], 
carbonic anhydrase inhibitors, which were employed in cocrystal protein studies, e.g. 
3,[14] and the antimalarial, ferroquine 4[15], which acts on chloroquine-resistant 
malaria (Figure 1). Compound 4 has advanced to Phase II clinical trials for malaria in 
combination therapy[16–18] whereas the ferrocifens are progressing towards clinical 
































Fig. 1. Representative examples of ferrocenes in medicinal chemistry. 
Finally, many ligands, such as the η5-bound cyclopentadienyl series, are rather large 
and the resulting steric clashes may drive selectivity and favour interactions in 
hydrophobic areas[19],[20]. In this regard, we recently continued a very fruitful 
collaboration with colleagues at Lille-2 University, France, which focussed on the 
design of inverse agonists of the canabinnoid CB2 receptor, a well-studied G-protein 
coupled receptor (GPCR), as well as of ligands acting on fatty acid amide hydrolase 
(FAAH). [21–23],[24] Our efforts culminated in a suitable illustration of aminoferrocene 
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Fig. 2. Similar activity of bulky amide substituents vs a GPCR target. 
Our ferrocene-based research efforts  mostly concentrate on targeting cancer drivers 
through replacement of aromatic or heteroaromatic groups in small-molecule drugs or 
lead compounds by an “escape from flatland”[25] ferrocene group. Our initial studies 
involved generating analogues based around sunitinib[26], a marketed anti-
angiogenesis inhibitor, which acts on a number of kinase targets (Fig. 3). We replaced 











































Fig. 3. Marketed kinase inhibitors. 
 During these early studies, we were effectively conducting “fishing” exercises with 
little structural or mechanistic know-how and conducting random kinase assay 
screens. Some of the compounds had submicromolar potency and the commercial 
assays were quite expensive, limiting our scope. Moreover, cell-based data such as 
GI50 values, although useful, give little information on actual kinase inhibition as they 
might be due to non-specific action or toxicity. Nevertheless, the synthetic endeavours 
led to a number of new air- and water-stable organometallic complexes, many 
characterised in the solid state and synthesised by microwave-mediated 
chemistry.[29,30],[31] 
Since this initial work, we have made a number of ferrocene-based molecules (Fig. 4). 
Many are oxindole derivatives, including the pentasulfanyl analogue, 8[32]. Such SF5 
bioisosteres are becoming more prevalent in materials and medicinal chemistry[33,34] 
and we expect them to be exploited more in bioorganometallic chemistry since they 
form an octahedral complex at sulphur, which is very amenable to X-ray 
crystallography and are useful as 19F NMR probes, and starting materials containing 
a SF5 group are now more commonly available. Moreover, to test the steric limits of 
this inhibitor scaffold, we synthesised compounds 9[35] and 10[36]. Indeed, the mixed 
sandwich cobalt analogue 10 was too big to fit in even some of the largest kinase ATP 
pockets, a result that validated our predictive space filling model. In fact, in many 
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cases, similar docking studies utilising published kinase crystal structures were used 
to guide our design process. Compounds 11[37] and 12[38] were vaguely linked to 
Iressa[39] (Fig. 3) and a MnK12 inhibitor[40], respectively, and showed reasonable 
activities, although the desired ferrocene-based Mnk inhibitor failed to inhibit Mnk. It 
exhibited reasonable inhibitory activity in cells; however, this emphasises that caution 
must be made to avoid over-reliance on indirect cellular assays reporting phenotypic 
























































 Fig. 4. Other kinase inhibitors made in our laboratory. 
 
We were probably the first group to rationally design a metal-based analogue of 
SAHA, 13, a histone deacetylase inhibitor (HDACi), by using ferrocene as the aryl cap 
(Scheme 2, Fig. 5). We called the analogue JAHA and this was followed by a click-
JAHA[41,42,42,43],[44]. HDACis tend to comprise such a cap, a linker and a zinc 
binding group (ZBG)[45]. Reports of a gold-based HDAC inhibitor[46] and a dual action 
SAHA-cis platin-like hybrid[47] preceded our study. All JAHAs showed good HDAC 
inhibition, cellular activity and we were able to rationalise binding by docking studies. 
However, like many HDACis, they inhibited several HDACs and the quest for isoform-
selective[48], even specific, inhibitors is desirable in terms of reducing off-target effects 
and in the development of chemical probe (or tool) compounds[49,50] for elucidating 

















Scheme 2. Synthesis of JAHA. 
The HDAC3 selective Pojamide 16[51] was synthesized in our laboratory. Related 
HDAC3 isoform-selective inhibitors have many uses in cancer and in the 
CNS[52],[53],[54]. The presence of the ferrocene moiety in 16 also affords us with the 





































Fig. 5. HDAC3 Selective Inhibitors compared with JAHA and SAHA. 
 
Conclusions. We have had an interest in metal-containing analogues of bioactive 
molecules for over a decade. The area has significantly evolved since we started our 
work, with more rational design of complexes, greater synthetic scope and 
improvements in enzyme docking and X-ray crystallography techniques. With these 
advancements in the field also comes a  better understanding of the pharmacokinetic 
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